There are currently 54 clinical trials in Newport News, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Peninsula Cancer Institute, Health Research of Hampton Roads, Inc, Virginia Oncology Associates and Peninsula Cancer Institute-Newport News. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/08/2024
Locations: Mayview Hospital LLC d/b/a Bon Secours Liver Institute of Hampton Roads, Newport News, Virginia
Conditions: Primary Biliary Cholangitis
Register for Updates
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
NCT06060665
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/08/2024
Locations: Mayview Hospital LLC d/b/a Bon Secours Liver Institute of Hampton Roads, Newport News, Virginia
Conditions: Primary Biliary Cholangitis
Register for Updates
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Health Res of Hampton Roads, Newport News, Virginia
Conditions: Obesity
Register for Updates
A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
NCT05952856
Recruiting
The goal of this study is to evaluate the efficacy, safety, and tolerability of MK-0616 in adult participants with hypercholesterolemia. The primary hypothesis is that MK-0616 is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Health Research of Hampton Roads, Inc. ( Site 0044), Newport News, Virginia
Conditions: Hypercholesterolemia, Familial Hypercholesterolemia
Register for Updates
MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756
Recruiting
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of MK-0616 compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Health Research of Hampton Roads, Inc. ( Site 0043), Newport News, Virginia
Conditions: Arteriosclerosis, Hypercholesterolaemia
Register for Updates
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: TPMG Rheumatology/TPMG Clinical Research, Newport News, Virginia
Conditions: Rheumatoid Arthritis
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Peninsula Cancer Institute-Newport News, Newport News, Virginia
Conditions: Stage III Colon Cancer
Register for Updates
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT06323174
Recruiting
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: TPMG Clinical Research, Newport News, Virginia
Conditions: Type 2 Diabetes
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
03/29/2024
Locations: Research Site, Newport News, Virginia
Conditions: Asthma
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Virginia Oncology Associates,1051 Loftis Blvd Suite 100, Newport News, Virginia
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227
Recruiting
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dumm... Read More
Gender:
All
Ages:
Between 6 years and 18 years
Trial Updated:
03/26/2024
Locations: Health Res of Hampton Roads, Newport News, Virginia +1 locations
Conditions: Obesity
Register for Updates
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
NCT04496739
Recruiting
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are designed to improve informed choice about breast cancer chemoprevention. Recognizing barriers and facilitators that can influence the adoption of decision support tools at recruitment centers may help researchers learn how to best implement them into clinical practice.
Gender:
All
Ages:
All
Trial Updated:
03/18/2024
Locations: Peninsula Cancer Institute-Newport News, Newport News, Virginia
Conditions: Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
Register for Updates